InMed's INM-901 reduces neuroinflammation markers in Alzheimer's ex vivo study

InMed Pharmaceuticals Inc.

INM-901 statistically significantly reduced pro-inflammatory cytokines IL-6, IL-1β, IL-2, and KC/Gro in LPS-induced ex vivo model.
INM-901 significantly reduced inflammasome marker NLRP3, a key contributor to neurodegeneration.
Reduction of pro-inflammatory markers independent of amyloid beta or tau pathology.
Company plans to advance INM-901 through additional preclinical studies with IND-enabling studies to follow.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.